Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Does Incyte Corporation (INCY) Deserve Its New Valuation?

Page 1 of 2

One of the hottest stocks on the market Wednesday was Incyte Corporation (NASDAQ:INCY), a pharmaceutical company specializing in the development of JAK inhibitors. It erupted by as much as 32% in mid-day trading after releasing promising data from a phase 2a proof-of-concept trial evaluating one of its JAK inhibitors, Jakafi (ruxolitinib), in pancreatic cancer. As fellow health-care Fool Keith Speights explained, it could be a huge deal for the pancreatic cancer market. Still, investors may be wondering if Incyte really deserves its new valuation. Let’s evaluate the pipeline and see what we find.

Incyte Corporation (NASDAQ:INCY)

Run home JAK
What the heck is a JAK inhibitor, anyway? Drugs in the class are small molecules that interrupt the JAK pathway in cells, which is responsible for sending and receiving messages from the body’s immune system. The biochemical importance of the pathway makes it a great candidate for treating oncology and inflammatory diseases — exactly what Incyte has set out to do.

anImage
The pipeline above is current as of August 8, 2013. Source: Incyte website

Incyte Corporation (NASDAQ:INCY) has largely split its burgeoning pipeline between two pharmaceutical giants: Novartis AG (ADR) (NYSE:NVSfor oncology, and Jakafi and Eli Lilly & Co. (NYSE:LLYfor inflammation. Both partners provide funding, cost-sharing, and legitimacy to management’s vision for its pipeline. All one needs to do is consider what would happen if the company’s three JAK inhibitors — Jakafi, baricitinib, and INCB39110 — are successful.

Already approved for myelofibrosis, Jakafi netted Novartis AG (ADR) (NYSE:NVS) and Incyte $136 million in 2012, and $102 million in the first six months of 2013. One day cracking the pancreatic cancer market would open up a $1.2 billion opportunity with relatively few competitors. The pair is also evaluating Jakafi in polycythemia vera and hematologic tumors, which could add another several hundred million dollars to the product’s revenue potential.

The biggest opportunity may lie in treating inflammatory diseases. Incyte Corporation (NASDAQ:INCY) and Eli Lilly & Co. (NYSE:LLY) don’t have a marketable product yet, but effectively treating rheumatoid arthritis — the most advanced indication being evaluated — could be worth billions. Consider that the Big Three TNF-alpha biologics — Remicade, Enbrel, and Humira — approved for such indications brought in a combined $19.6 billion in sales in 2012. Each is approved for multiple indications, but each also had to work its way up from the bottom. Translation: Eli Lilly and Incyte could be sitting on billions of dollars in potential future revenue.

Pfizer Inc. (NYSE:PFEwas the first — and only — company to bring a JAK inhibitor to the rheumatoid arthritis market. Xeljanz has gotten off to a slower start than anticipated, but analysts such as Catherine Arnold at Credit-Suisse are still pegging peak annual sales to $2.6 billion. Others are confident it can help shake-up a market dominated by expensive (but effective) biologic treatments. The nearly $3 billion in potential is not bad for a single indication, and potentially good news for Incyte Corporation (NASDAQ:INCY) investors.

Page 1 of 2
Loading Comments...